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Abstract: Neurodevelopmental disorders (NDDs) are characterized by cognitive, social and 
motor deficits and are highly comorbid with intractable epilepsies. Through advances in 
genetic sequencing technologies a vast number of genes have been implicated in NDDs. 
State-of-the-art gene-editing techniques have led to the generation of hundreds of mouse 
models of NDDs. As an example, rodent models of Rett and Dravet syndromes as well as 
the syndromes caused by mutations in CDKL5 and Syngap1 display cognitive deficits in 
conjunction with seizure phenotypes. These models allow researchers to understand the 
underlying mechanisms as well as develop novel treatment strategies that can potentially be 
translated to the clinic. Furthermore, it may be possible to gain insights into the contribution 
of epilepsy to the progression of cognitive, social and motor phenotypes in NDDs.  
Keywords (6): Neurodevelopmental disorders, epilepsy, MECP2, SCN1A, CDKL5, 
SYNGAP1. 
 
 
1.0 Introduction 
Neurodevelopmental disorders (NDDs) including autism spectrum disorders (ASDs) and 
intellectual disability (ID) can affect cognitive, social and motor abilities1.  NDDs are 
commonly associated with severe and intractable epilepsies with approximately 26% of 
patients having seizure comorbidities1. Thus far, even if anti-epileptic drugs (AEDs) are 
effective in treating seizures, it is unclear whether neurodevelopmental symptoms are 
improved upon seizure control.  
Recent advances in genetic sequencing have identified over 100 genes2–4 implicated in 
syndromic ASD and a further 700 x-linked, autosomal-dominant and autosomal-recessive 
genes that can be utilized to diagnose NDDs5–7. Coinciding with an increase in clinical data 
on the association of these genes with NDDs and epilepsy, gene-editing technologies such 
as CRISPR-Cas9 have made it increasingly faster, accurate and inexpensive to generate 
rodent models of these disorders with over 250 mouse models generated to study ASD 
alone8,9, 
Animal models allow researchers to investigate the underlying mechanisms of these 
disorders, identify biomarkers for the clinic and develop potential novel treatment strategies. 
Furthermore, as many of the genes identified converge across biological pathways, it is 
important to define whether this results in symptomatic convergence and therefore possible 
common treatments. 
For animal models to be effective it is necessary that they display face validity that 
resembles symptoms in patients. Although genes in brain disorders are frequently conserved 
in rodents, their function in other species may not be as critical to the complex behavioural 
disabilities associated with NDDs. Furthermore, it is possible that compensatory 
mechanisms come into effect upon gene-editing which are not present or have more of an 
impact than compensation in patients. Nonetheless, mouse models have shown the highest 
level of construct validity across species so far tested10–12  
As recently reviewed by Silverman and Ellegood12, deficits in many behavioural assays in 
rodent models of NDDs pertinent to ASD and ID include social communication experiments 
such as the three-chambered approach, reciprocal dyad interactions, social recognition, 
social place preference, and ultrasonic vocalizations. Cognitive inflexibility and insistence on 
sameness has also been modelled in NDD models13,14. Other relevant behavioural deficits 
found in mouse models include quantification of spontaneous behaviours such as self-
grooming, circling, jumping, back flipping and overall hyperactivity, which may be linked to 
abnormal or epileptic brain network activity.  
Spontaneous epileptic activity has been recorded both through behavioural monitoring and 
electrophysiology in multiple genetically modified mouse models of NDDs15–18. A range of 
spontaneously emerging seizure types have been reported including tonic-clonic, atypical 
and typical absence, myoclonic spasms and interictal spikes. Increases in susceptibility to 
audiogenic seizures, hyperthermia and chemically induced seizures is also prevalent across 
genetic rodent models of NDDs18–23. These models offer the opportunity to test the effect of 
anti-epileptic drugs (AEDs) and to disentangle the contribution of seizures to the progression 
of NDD’s cognitive, social and motor phenotypes. Below, we summarize findings about 
epileptic activity in four mouse models of NDDs. 
2.1 methyl-CpG-binding protein 2 (MECP2)  
In Rett syndrome, both ID and ASD develop due to gain and loss of function of the X-linked 
MECP2 gene. Patients develop progressive dementia, infantile hypotonia, gait abnormalities 
and seizures following normal early development for the first 2 years of life24. Approximately 
half of patients with MECP2 gene duplication suffer from epilepsy during their lifetime with a 
high level of refractoriness of approximately 32 to 56%25,26.   Lennox-Gastaut syndrome, in 
which patients suffer from a variety of seizure types is the most common form of epilepsy in 
patients with MECP2 duplication.  Whereas patients with late truncating deletions have a 
lower prevalence of epilepsy, several mutations exist with varying risks for epilepsy. 
Mouse and rat models of MECP2 overexpression and duplication reliably replicate the 
seizure phenotype15,16, with animals developing tonic-clonic seizures and increasing the 
sensitivity to pentylenetetrazole (PTZ)-induced and kainic acid-induced seizures. Loss of 
function models display cortical discharges consistent with absence epilepsy19.  
Seizure and ND phenotypes are reversable in Rett syndrome rodent models utilizing gene 
modification strategies27,28 and implementation of gene therapy in the clinic may be soon 
attainable. Pharmacological strategies that target downstream targets of MECP2 are also 
possible but made difficult to implement as the exact function of the gene is still unknown. 
Nonetheless, the effectiveness of AEDs in treating seizures in Rett syndrome have not been 
extensively tested in rodent models and could inform clinicians on potential therapeutics for 
Rett syndrome.  
2.2 SCN1A 
Dravet syndrome is a rare form of epilepsy accompanied by neurodevelopmental deficits 
and is mediated by the SCN1A gene, which encodes for the alpha subunit of the voltage-
gated sodium channel29. The syndrome is characterised by multiple seizure types including 
febrile and febrile generalised tonic-clonic and focal-clonic, tonic, status epilepticus, 
myoclonic and atypical absences. The epileptic symptoms are highly refractory to AEDs and 
the onset of the disease occurs within the first year of life30. 
As recently reviewed by Griffen at al.31, multiple mouse models of Dravet with SCN1A loss of 
function exist. Rodent models display ictal and interictal activity, as well as myoclonic jerks 
and flexions17. Seizures in SCN1A knock-out mice are also inducible via hyperthermia20. 
First line AEDs are ineffective in treating seizures and sodium channel modulators such as 
carbamazepine are known to exacerbate seizures32. However, recent clinical trials show 
positive seizure reduction utilizing stiripentol, cannabidiol, and fenfluramine with 50 to 70% 
reduction in seizures and nearly a quarter of patients attaining seizure freedom33. In mouse 
models, stiripentol iw effective in reducing hyperthermia-induced seizures34, while 
cannabidiol similarly reduced spontaneous seizures35. Fenfluramine was found to be 
effective in a zebrafish model of Dravet36.   
Successful face validity of Dravet animal models suggests that novel treatments to achieve a 
higher level of seizure control and reversal of neurodevelopmental deficits may be possible. 
Studies to modify gene expression in rodent models of Dravet Syndrome have shown to 
effectively reduce seizures37.  The utility of animal models in Dravet is therefore likely to yield 
fruitful new treatment paths to test in the clinic.  
2.3 cyclin-dependent kinase-like-5 (CDKL5) 
CDKL5 is likely involved in correct dendritic spine structure and synapse activity in excitatory 
neurons by binding and phosphorylating the NGL-1 cell adhesion molecule which allows it to 
form a stable association with PSD9538. CDKL5 is amongst the most common single-gene 
predictors of epilepsy diagnosis39. Mutations in CDKL5 lead to a NDD with severe 
developmental delay and early-onset epilepsy. Other features include impaired hand 
function with stereotypies, impaired social interaction with autistic features and severe motor 
impairment with only exceptional patients who are independently ambulant40. 98% of 
patients present with a history of epilepsy including infantile spasms, myoclonus and 
prolonged generalized tonic-clonic seizures41. Most of these types of epilepsy appear to be 
refractory to AEDs.  
CDKL5 models have been generated and display certain phenotypes including 
hyperexcitability21, visual impairments42, social interaction deficits, motor control decreases 
and loss of fear memory43. Nonetheless, despite the prevalence of seizures in patients, 
mouse models have not been reported to display spontaneous ictal or interictal activity. It is 
likely that either compensatory mechanisms exist to compensate CDKL5 loss of function or 
the gene does not play as critical a role in rodents. CDKL5 mice however are susceptible to 
NMDA-induced seizures21. More research is necessary to elucidate whether animal models 
of this disorder have translational value.  
2.4 SYNGAP1 
SYNGAP1 is associated with NMDAR-activated Ras signalling dynamics in dendritic spines 
as well as AMPA receptor membrane insertion23,44. Although mutations are relatively rare, 
heterozygous loss-of-function in SYNGAP1 results in a genetically defined NDD with ID, 
which also predisposes patients to ASD. Symptoms of this syndrome include cognitive 
impairment, loss of language abilities and seizures45,46. In a recent clinical report, 56 of 57 
patients had epilepsy with a median age of onset of 2 years47. Most seizures are 
generalized, with absence seizures reported in 53 of the patients, although focal seizures 
also occur. 65% of patients had intractable epilepsy with valproate and lamotrigine 
commonly prescribed as well as cannabidiol. 
As found in patients48, mouse models display increased risk-taking behaviours as assessed 
by the elevated plus maze as well as cognitive and  learning impairments45. SYNGAP1 
haploinsufficient mice have spontaneous interictal activity and have a reduced fluorothyl-
induced seizure threshold as well as being prone to audiogenic seizures18,22,23. Restoration 
of the gene in adult mice is able to improve behavioural and electrophysiological measures 
of memory and seizures18. More work is needed to test potential treatment strategies in 
these animals and determine whether these are translatable to the clinic.  
3.0 Conclusion 
Rodent models display phenotypes reminiscent of symptoms in genetically defined NDDs 
such as those affecting cognition, motor abilities and sociability. Genetically defined NDDs 
very frequently are comorbid with severe intractable epilepsy. Brain network dysfunction 
resulting in seizure activity is common in rodent models. Furthermore, if spontaneous 
epilepsy is absent, such as in the case of CDKL5 models, the mutant animals can still be 
challenged to determine whether they have compromised seizure thresholds.  
Pharmacology treatments as well as other strategies such as gene therapy can be tested on 
rodent models and findings can be translated to the clinic as with the positive results of 
stiripentol34, cannabidiol35, and fenfluramine36 being effective in seizure control in animal 
models. Rodents give researchers the opportunity to develop new treatments by probing 
deeper into the mechanisms resulting in NDDs. An enticing avenue of research with rodent 
genetic models of NDDs is to test the hypothesis that if seizures are controlled early enough 
in development, they are able to arrest the neurodevelopmental deficits.     
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